Current developments in the use of biomarkers for juvenile idiopathic arthritis topical collection on pediatric rheumatology

Current Rheumatology Reports

Volumn 16, Issue 3, 2014, Pages

  Duurland, Chantal L ^a   Wedderburn, Lucy R ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; CRP; ESR; JIA; Juvenile idiopathic arthritis; Methotrexate; MRP; MTX; Remission; S100; SNP; Treatment

Indexed keywords

BIOLOGICAL MARKER; GLUCOCORTICOID; MESSENGER RNA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT;

ARTICLE; DISEASE COURSE; DISEASE SEVERITY; GENOTYPE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PHENOTYPE; QUALITY OF LIFE; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; METABOLISM; PROGNOSIS; REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; PHENOTYPE; PROGNOSIS; REMISSION INDUCTION;

EID: 84894610212     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0406-3     Document Type: Article

References (43)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-78. doi: 10.1016/s0140-6736(07)60363-8.
2. Petty RE, Southwood TR, Manners P, et al. Internation League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis: Second Revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-2. (Pubitemid 38160763)
3. Klassen TP, Hartling L, Craig JC, et al. Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Med. 2008;5(8):e172. doi: 10.1371/journal.pmed.0050172.
4. Goldman J, Becker ML, Jones B, et al. Development of biomarkers to optimize pediatric patient management: what makes children different? Biomark Med. 2011;5(6):781-94.
5. Moncrieffe H, Ursu S, Holzinger D, et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford). 2013;52(8):1467-76. doi: 10.1093/rheumatology/ket152.
6. Thomson W, Barrett JH, Donn R, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology (Oxford). 2002;41:1183-9. (Pubitemid 35203549)
7. Ringold S, Seidel KD, Koepsell TD, et al. Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford). 2009;48(8):972-7. doi: 10.1093/rheumatology/kep144.
8. Kotaniemi K, Arkela-Kautiainen M, Haapasaari J, et al. Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients. Ann Rheum Dis. 2005;64(6):871-4. doi: 10.1136/ard.2004.026955. (Pubitemid 40733911)
9. Heiligenhaus A, Heinz C, Edelsten C, et al. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm. 2013;21(3):180-91.
10. Angeles-Han ST, Pelajo CF, Vogler LB, et al. Risk Markers of Juvenile Idiopathic Arthritis-associated Uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol. 2013;40(12):2088-96. doi: 10.3899/jrheum.130302.
11. Online document https://www.bspar.org.uk/DocStore/FileLibrary/PDFs/ BSPAR%20Guidelines%20for%20Eye%20Screening%202006.pdf
12. Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford). 2011;50(1):189-95. doi: 10.1093/rheumatology/keq308.
13. De Kleer IM, Wedderburn LR, Taams LS, et al. CD4 + CD25bright Regulatory T cells Actively Regulate Inflammation in the Joints of Patients with the Remitting Form of Juvenile Idiopathic Arthritis. J Immunol. 2004;172:6435-43. (Pubitemid 38621253)
14. Nistala K, Moncrieffe H, Newton KR, et al. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 2008;58(3):875-87. doi: 10.1002/art.23291. (Pubitemid 351364887)
15. Hunter PJ, Nistala K, Jina N, et al. Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression. Arthritis Rheum. 2010;62(3):896-907. doi: 10.1002/art.27284. This study revealed that immunological differences in the synovial milieu predate clinical extension, introducing the concept of "Extended-to-be-JIA" patients.
16. Gibson DS, Finnegan S, Jordan G, et al. Stratification and Monitoring of Juvenile Idiopathic Arthritis Patients by Synovial Proteome Analysis. J Proteome Res. 2009;8:5601-9.
17. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvment in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202-9. (Pubitemid 27430130)
18. Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658-66. doi: 10.1002/art.24516.
19. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum. 2004;50(12):3762-71. doi: 10.1002/art.20631. (Pubitemid 39643922)
20. Holzinger D, Frosch M, Kastrup A, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71(6):974-80. doi: 10.1136/annrheumdis-2011-200598.
21. Ling XB, Park JL, Carroll T, et al. Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications. Proteomics. 2010;10(24):4415-30. doi: 10.1002/pmic.201000298.
22. Ling XB, Lau K, Deshpande C, et al. Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis. Clin Proteomics. 2010;6(4):175-93. doi: 10.1007/s12014-010-9058-8. This study considered the feasibility of measuring potential biomarkers in the urine of sJIA patients by examining the urine peptidome for factors which could discriminate between active or quiescent disease state and disease remission.
23. Ravelli A, Grom AA, Behrens EM, et al. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immunol. 2012;13(4):289-98. doi: 10.1038/gene.2012.3.
24. Lehmberg K, Pink I, Eulenburg C, et al. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr. 2013;162(6):1245-51. doi: 10.1016/j.jpeds.2012.11.081. Describes already available measures which can be used to discriminate between MAS and other forms of HLH or virus-associated HLH.
25. Fall N, Barnes M, Thornton S, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007;56(11):3793-804. doi: 10.1002/art.22981. (Pubitemid 350100712)
26. Beukelman T, Patkar NM, Saag KG, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465-82.
27. Foster HE, Marshall N, Myers A, et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003;48(3):767-75. doi: 10.1002/art.10863. (Pubitemid 36302014)
28. Duffy CM. Measurement of health status, functional status, and quality of life in children with juvenile idiopathic arthritis: clinical science for the pediatrician. Rheum Dis Clin N Am. 2007;33(3):389-402. doi: 10.1016/j.rdc.2007. 07.003. (Pubitemid 47532348)
29. Klein A, Kaul I, Foeldvari I, et al. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken). 2012;64(9):1349-56. doi: 10.1002/acr.21697.
30. Wittkowski H, Frosch M, Wulffraat N, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008;58(12):3924-31. doi: 10.1002/art.24137.
31. Hinks A, Moncrieffe H, Martin P, et al. Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann Rheum Dis. 2011;70(8):1395-400. doi: 10.1136/ard.2010.146191.
32. de Rotte MC, Bulatovic M, Heijstek MW, et al. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J Rheumatol. 2012;39(10):2032-40. doi: 10.3899/jrheum.111593.
33. Moncrieffe H, Hinks A, Ursu S, et al. Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype. Pharmacogenet Genomics. 2010;20(11):665-76. doi: 10.1097/FPC.0b013e32833f2cd0.
34. Bulatovic M, Heijstek MW, Van Dijkhuizen EH, et al. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71(9):1484-9. doi: 10.1136/annrheumdis-2011- 200942. This study designed and tested a prediction model combining clinical and genetic variables to predict response to MTX.
35. Wallace CA, Ravelli A, Huang B, et al. Preliminary Validation of Clinical Remission Criteria using the OMERACT Filter for Select Categories of Juvenile Idiopathic Arthritis. J Rheumatol. 2006;33:789-95.
36. Wallace CA, Ruperto N, Giannini EH. Preliminary Criteria for Clinical Remission for Select Categories of Juvenile Idiopathich Arthritis. J Rheumatol. 2004;31:2290-4. (Pubitemid 39453253)
37. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate Withdrawal at 6 vs 12 Months in Juvenile Idiopathic Arthritis in Remission. JAMA. 2010;303(13):1266-73. This study was the first proof of concept that a serum biomarker can be used to predict risk of flare upon withdrawal of medication for JIA.
38. Foell D, Frosh M. Schulze zur Wiesch A et al. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis. 2004;63(2):206-8. (Pubitemid 38122142)
39. Schulze zur Wiesch A, Foell D, Frosh M, et al. Myeloid related proteins MRP8/14 may predict disease flares in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004;22:368-73. (Pubitemid 38585243)
40. Gerss J, Roth J, Holzinger D, et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis. 2012;71(12):1991-7. doi: 10.1136/annrheumdis-2012-201329.
41. Wallace CA, Huang B, Bandeira M, et al. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(11):3554-62. doi: 10.1002/art.21389. (Pubitemid 41612224)
42. Knowlton N, Jiang K, Frank MB, et al. The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum. 2009;60(3):892-900. doi: 10.1002/art.24298.
43. Jiang K, Frank MB, Chen Y, et al. Genomic characterization of remission in juvenile idiopathic arthritis. Arthritis Res Ther. 2013;15(4):R100. doi: 10.1186/ar4280.